Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Pembrolizumab |
Indication/Tumor Type | lung small cell carcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | lung small cell carcinoma | sensitive | Pembrolizumab | Phase I | Actionable | In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment resulted in an objective response rate of 33% (8/24) in patients with lung small cell carcinoma expressing CD274 (PD-L1) in 1% or more of tumor or stromal cells by IHC, including one patient with a complete response and seven patients with a partial response (PMID: 28813164; NCT02054806). | 28813164 |
CD274 positive | lung small cell carcinoma | sensitive | Pembrolizumab | Phase II | Actionable | In a Phase II trial (KEYNOTE-158), Keytruda (pembrolizumab) treatment resulted in superior objective response rate (35.7%, 15/24 vs 6.0%, 3/50), median progression-free survival (2.1 vs 1.9 months), and median overall survival (14.6 vs 7.7 months) in patients with CD274 (PD-L1)-positive (combined positive score>=1) advanced small cell lung cancer compared to patients with CD274 (PD-L1)-negative tumors (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 8506-8506; NCT02628067). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
(28813164) | Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study. | Full reference... |
Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158 | Full reference... |